UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

October 01, 2013

Date of Report (Date of earliest event reported)

IMMUNOTECH LABORATORIES, INC.

(Exact name of registrant as specified in its charter)


Nevada	333-57514	95-4834274

(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification Number)



120 W. Pomona Ave. Monrovia, California		91016

(Address of principal executive offices)		(Zip Code)

(818) 409-9091

Registrant’s telephone number, including area code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


[ ]		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into Material Definitive Agreement

IMMUNOTECH Laboratories Inc. (IMMB) has signed a Special Private Placement Agreement (SPPA) for equity line funding with World Finance Capital Holdings Inc. (WFC) to obtain S-1 registration.

Item 9.01 Financial Statements and Exhibits

Exhibit

Number Description

99.1 Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


		IMMUNOTECH LABORATORIES, INC.
Date: October 01, 2013	By:	/s/ Harry Zhabilov
		Harry Zhabilov
		President

Immunotech Laboratories, Inc. 8-K